Treatment of human disease by adeno-associated viral gene transfer.

Human Genetics
Kenneth H Warrington, R W Herzog

Abstract

During the past decade, in vivo administration of viral gene transfer vectors for treatment of numerous human diseases has been brought from bench to bedside in the form of clinical trials, mostly aimed at establishing the safety of the protocol. In preclinical studies in animal models of human disease, adeno-associated viral (AAV) vectors have emerged as a favored gene transfer system for this approach. These vectors are derived from a replication-deficient, non-pathogenic parvovirus with a single-stranded DNA genome. Efficient gene transfer to numerous target cells and tissues has been described. AAV is particularly efficient in transduction of non-dividing cells, and the vector genome persists predominantly in episomal forms. Substantial correction, and in some instances complete cure, of genetic disease has been obtained in animal models of hemophilia, lysosomal storage disorders, retinal diseases, disorders of the central nervous system, and other diseases. Therapeutic expression often lasted for months to years. Treatments of genetic disorders, cancer, and other acquired diseases are summarized in this review. Vector development, results in animals, early clinical experience, as well as potential hurdles and challenges ar...Continue Reading

References

Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·B C TrapnellR G Crystal
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·R J SamulskiN Muzyczka
Nov 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·T R FlotteB J Carter
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·D W RussellA D Miller
Aug 1, 1993·The Journal of Cell Biology·J M Ervasti, K P Campbell
Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·B J PetrofH L Sweeney
Oct 1, 1995·Human Gene Therapy·K R ClarkP R Johnson
May 1, 1996·Journal of Virology·S A AfioneT R Flotte
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·R M LindenK I Berns
Oct 15, 1996·Proceedings of the National Academy of Sciences of the United States of America·R M LindenK I Berns
Mar 1, 1997·Nature Medicine·K J FisherJ M Wilson
Jun 1, 1997·Muscle & Nerve·S D WiltonN G Laing
May 27, 1997·Proceedings of the National Academy of Sciences of the United States of America·R W HerzogK A High
Oct 6, 1997·Proceedings of the National Academy of Sciences of the United States of America·K QingA Srivastava
Feb 12, 1998·Proceedings of the National Academy of Sciences of the United States of America·J E MurphyV J Dwarki
Nov 25, 1998·Proceedings of the National Academy of Sciences of the United States of America·S SongT R Flotte

❮ Previous
Next ❯

Citations

Jan 25, 2008·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Dirk M Nettelbeck
Mar 17, 2007·Current Hypertension Reports·Yi ChuDonald D Heistad
Oct 3, 2006·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kim Van VlietRichard O Snyder
Jun 23, 2009·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·J-P SallesE Gouze
Dec 17, 2008·Gene Therapy·J A CirelliW V Giannobile
Oct 2, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Samuel L MurphyKatherine A High
Oct 23, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bernd HauckJ Fraser Wright
Dec 11, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Chun-Chi ChenMi-Hua Tao
Apr 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Haifeng Chen
Dec 31, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zejing WangStephen J Tapscott
Nov 24, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Ping-Jie XiaoR Jude Samulski
Jan 19, 2008·Cancer Gene Therapy·L KrügerJ A Kleinschmidt
Jul 12, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Devang ThakorIchiro Nishimura
Oct 24, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Alessandra TessitoreAlberto Auricchio
Jan 29, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Edmund R HollisMark H Tuszynski
Jan 9, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Stéphanie LorainLuis Garcia
May 31, 2008·Proceedings of the National Academy of Sciences of the United States of America·Li ZhongArun Srivastava
Mar 19, 2009·ILAR Journal·Zejing WangRainer Storb
Dec 2, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Daxiong ZengWeining Xiong
Mar 28, 2008·Journal of Virology·Nina DiPrimioR Jude Samulski
Nov 13, 2008·Molecular Cancer Therapeutics·Shawn HingtgenKhalid Shah
Apr 17, 2008·The Journal of Clinical Investigation·Mariacarmela AlloccaAlberto Auricchio
Oct 3, 2013·PloS One·Joseph TellezChristopher D Porada
Mar 1, 2009·Immunotherapy·Torbjörn Ramqvist, Tina Dalianis
Oct 17, 2013·European Journal of Internal Medicine·Pol F Boudes
Jul 17, 2012·Human Gene Therapy·Barry J ByrneCathryn S Mah
Feb 6, 2010·Expert Opinion on Biological Therapy·Ying TangBing Wang
Jan 17, 2007·Expert Opinion on Biological Therapy·Gloria Gonzalez-AseguinolazaAstrid Paneda
Apr 23, 2008·Expert Opinion on Drug Delivery·Chun Wang, Phuong-Truc Pham
Mar 5, 2016·Frontiers in Molecular Neuroscience·Georg von JonquieresMatthias Klugmann

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.